UY35390A - Compuestos con actividad anti-hcv y composiciones farmacéuticas que los contienen - Google Patents

Compuestos con actividad anti-hcv y composiciones farmacéuticas que los contienen

Info

Publication number
UY35390A
UY35390A UY0001035390A UY35390A UY35390A UY 35390 A UY35390 A UY 35390A UY 0001035390 A UY0001035390 A UY 0001035390A UY 35390 A UY35390 A UY 35390A UY 35390 A UY35390 A UY 35390A
Authority
UY
Uruguay
Prior art keywords
compounds
contain
pharmaceutical compositions
hcv activity
hcv
Prior art date
Application number
UY0001035390A
Other languages
English (en)
Inventor
John F Kadow
Kyle J Eastman
Kyle E Parcella
Original Assignee
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Publication of UY35390A publication Critical patent/UY35390A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La descripción proporciona compuestos de la fórmula I, incluyendo sus sales, así como composiciones y métodos de uso de los compuestos. Los compuestos tienen actividad contra el virus de hepatitis C (HCV) y pueden ser de utilidad para el tratamien to de aquellos infectados con HCV.
UY0001035390A 2013-03-13 2014-03-12 Compuestos con actividad anti-hcv y composiciones farmacéuticas que los contienen UY35390A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778936P 2013-03-13 2013-03-13
US201361915729P 2013-12-13 2013-12-13

Publications (1)

Publication Number Publication Date
UY35390A true UY35390A (es) 2014-09-30

Family

ID=50819936

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035390A UY35390A (es) 2013-03-13 2014-03-12 Compuestos con actividad anti-hcv y composiciones farmacéuticas que los contienen

Country Status (6)

Country Link
US (1) US8962651B2 (es)
EP (1) EP2970322B1 (es)
ES (1) ES2618811T3 (es)
TW (1) TW201518302A (es)
UY (1) UY35390A (es)
WO (1) WO2014164968A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3119769A1 (en) * 2014-03-21 2017-01-25 Bristol-Myers Squibb Pharma Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
EP3180346A1 (en) * 2014-08-05 2017-06-21 Bristol-Myers Squibb Company Furopyridine compounds for the treatment of hepatitis c
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
CN111153907A (zh) * 2020-01-09 2020-05-15 天津科技大学 丙肝病毒ns5b聚合酶抑制剂bmt-052关键中间体的高效合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009943B1 (ru) 2002-11-01 2008-04-28 Вирофарма Инкорпорейтед Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита с, и связанных с ним заболеваний
AU2009214194B2 (en) 2008-02-14 2012-05-17 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP5572725B2 (ja) * 2010-03-10 2014-08-13 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の処置のための化合物

Also Published As

Publication number Publication date
US20140275154A1 (en) 2014-09-18
TW201518302A (zh) 2015-05-16
ES2618811T3 (es) 2017-06-22
EP2970322A1 (en) 2016-01-20
WO2014164968A1 (en) 2014-10-09
US8962651B2 (en) 2015-02-24
EP2970322B1 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
CL2016000381A1 (es) Compuestos antivirales
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CR20160237A (es) Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2018000515A1 (es) Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015)
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
CR20150085A (es) Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
ECSP15000435A (es) Inhibidores macrocíclicos de virus flaviviridae
CL2015003370A1 (es) Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
UY35300A (es) Formulación de combinación de dos compuestos antivirales
ECSP12012103A (es) Inhibidores de virus flaviviridae.
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
CO7240410A2 (es) Inhibidores macrocíclicos de virus flaviviridae
EA201592081A1 (ru) СОЕДИНЕНИЯ НА ОСНОВЕ МИКРО-РНК И СПОСОБЫ МОДУЛИРОВАНИЯ АКТИВНОСТИ miR-122
CR20150447A (es) Nuevos derivados de pirazol
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
CL2015003357A1 (es) Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos
CR20150440A (es) Nuevos derivados de piridina